LPL Financial LLC Buys 233 Shares of Natera, Inc. (NASDAQ:NTRA)

LPL Financial LLC grew its holdings in Natera, Inc. (NASDAQ:NTRA) by 0.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 50,167 shares of the medical research company’s stock after purchasing an additional 233 shares during the quarter. LPL Financial LLC’s holdings in Natera were worth $2,441,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Harbor Capital Advisors Inc. acquired a new position in shares of Natera in the 2nd quarter valued at about $30,000. Quent Capital LLC lifted its stake in shares of Natera by 1,234.6% in the 2nd quarter. Quent Capital LLC now owns 1,081 shares of the medical research company’s stock valued at $53,000 after purchasing an additional 1,000 shares during the period. Belpointe Asset Management LLC lifted its stake in shares of Natera by 127.2% in the 1st quarter. Belpointe Asset Management LLC now owns 1,586 shares of the medical research company’s stock valued at $88,000 after purchasing an additional 888 shares during the period. First Horizon Advisors Inc. lifted its stake in shares of Natera by 74.4% in the 1st quarter. First Horizon Advisors Inc. now owns 1,594 shares of the medical research company’s stock valued at $88,000 after purchasing an additional 680 shares during the period. Finally, HWG Holdings LP lifted its stake in shares of Natera by 1,621.1% in the 1st quarter. HWG Holdings LP now owns 1,876 shares of the medical research company’s stock valued at $104,000 after purchasing an additional 1,767 shares during the period. 92.59% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Jonathan Sheena sold 10,000 shares of the company’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $60.01, for a total value of $600,100.00. Following the completion of the transaction, the insider now directly owns 494,746 shares of the company’s stock, valued at $29,689,707.46. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, insider Daniel Rabinowitz sold 732 shares of the company’s stock in a transaction that occurred on Thursday, September 28th. The stock was sold at an average price of $45.82, for a total value of $33,540.24. Following the completion of the transaction, the insider now directly owns 179,110 shares of the company’s stock, valued at $8,206,820.20. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Jonathan Sheena sold 10,000 shares of the stock in a transaction on Friday, September 1st. The shares were sold at an average price of $60.01, for a total value of $600,100.00. Following the transaction, the insider now directly owns 494,746 shares of the company’s stock, valued at $29,689,707.46. The disclosure for this sale can be found here. Insiders sold a total of 31,591 shares of company stock valued at $1,590,587 over the last three months. Corporate insiders own 9.42% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the company. StockNews.com started coverage on Natera in a research note on Thursday, October 5th. They issued a “sell” rating on the stock. The Goldman Sachs Group dropped their price target on Natera from $60.00 to $52.00 and set a “buy” rating on the stock in a research note on Friday, October 20th. Credit Suisse Group reaffirmed an “outperform” rating and set a $70.00 price target on shares of Natera in a research note on Friday, August 4th. Piper Sandler dropped their price target on Natera from $80.00 to $70.00 and set an “overweight” rating on the stock in a research note on Monday, October 16th. Finally, Morgan Stanley dropped their price target on Natera from $72.00 to $70.00 and set an “overweight” rating on the stock in a research note on Monday, August 7th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and six have issued a buy rating to the company. According to data from MarketBeat.com, Natera currently has a consensus rating of “Moderate Buy” and an average target price of $64.56.

Natera Stock Performance

Shares of Natera stock opened at $45.39 on Friday. The company has a market cap of $5.20 billion, a PE ratio of -9.42 and a beta of 1.18. Natera, Inc. has a 52 week low of $34.00 and a 52 week high of $63.00. The business has a 50 day moving average price of $46.07 and a 200-day moving average price of $49.06. The company has a quick ratio of 3.69, a current ratio of 3.85 and a debt-to-equity ratio of 0.47.

Natera (NASDAQ:NTRA) last issued its quarterly earnings data on Wednesday, November 8th. The medical research company reported ($0.95) EPS for the quarter, topping the consensus estimate of ($0.96) by $0.01. The firm had revenue of $268.30 million during the quarter, compared to the consensus estimate of $259.27 million. Natera had a negative return on equity of 88.47% and a negative net margin of 54.97%. The company’s quarterly revenue was up 27.4% compared to the same quarter last year. During the same period in the prior year, the business posted ($1.25) earnings per share. Equities analysts anticipate that Natera, Inc. will post -4.03 earnings per share for the current fiscal year.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.